Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
31 Octubre 2024 - 5:30AM
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company),
a commercial-stage company focused on addressing unmet needs for
the treatment of rare diseases, today announced it will report
third quarter financial results and provide a corporate update on
Tuesday, Nov. 12, 2024. The Company will issue a news release after
the market closes and host a conference call/audio webcast at 4:30
p.m. ET that day. The corporate update will include recent progress
with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as
the Company’s clinical stage programs.
A link to the audio webcast will be accessible
on the “Events & Presentations” page in the Investor Relations
section of Zevra’s website at https://investors.zevra.com/.
To join via telephone, please use the following
dial-in information:
- (800) 274-8461
(U.S.)
- +1 (203)
518-9814 (International)
- Conference ID:
ZVRAQ324
A replay of the webcast will be available for 90
days beginning at approximately 5:30 p.m. ET. The replay will be
accessible on the “Events & Presentations” page of Zevra’s
website at https://investors.zevra.com/.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage
rare disease company combining science, data, and patient needs to
create transformational therapies for diseases with limited or no
treatment options. Our mission is to bring life-changing
therapeutics to people living with rare diseases. With unique,
data-driven development and commercialization strategies, the
Company is overcoming complex drug development challenges to make
new therapies available to the rare disease community.
Expanded access programs are made available by
Zevra Therapeutics, Inc. and its affiliates and are subject to the
Company's Expanded Access Program (EAP) policy, as published on its
website. Participation in these programs is subject to the laws and
regulations of each jurisdiction under which each respective
program is operated. Eligibility for participation in any such
program is at the treating physician's discretion.
For more information, please
visit www.zevra.com or follow us
on X and LinkedIn.
Cautionary Note Concerning Forward-Looking
Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include all
statements that do not relate solely to historical or current
facts, including without limitation statements regarding upcoming
events or Zevra’s participation at such events. Forward-looking
statements are based on information currently available to Zevra
and its current plans or expectations. They are subject to several
known and unknown uncertainties, risks, and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. These and other important factors are described in
detail in the "Risk Factors" section of Zevra’s Annual Report on
Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly
Report for the quarter ended Sept. 30, 2024, and Zevra’s other
filings with the Securities and Exchange Commission. While we may
elect to update such forward-looking statements at some point in
the future, except as required by law, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Although we believe the expectations reflected in such
forward-looking statements are reasonable, we cannot assure that
such expectations will prove correct. These forward-looking
statements should not be relied upon as representing our views as
of any date after the date of this press release.
Zevra Contact
Nichol Ochsner+1 (732) 754-2545nochsner@zevra.com
Russo Partners Contact
David Schull+1 (858)
717-2310david.schull@russopartnersllc.com
Zevra Therapeutics (NASDAQ:ZVRA)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Zevra Therapeutics (NASDAQ:ZVRA)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024